Invesaro

Stocks Comparison

Cronos vs Niagen Bioscience: revenue, profit, margins and growth compared

Cronos brought in $193.4M of revenue in fiscal 2025, Niagen Bioscience $129.4M in fiscal 2025. Revenue changed by +19.5% at Cronos and +29.9% at Niagen Bioscience on the year before, so Niagen Bioscience grew faster. Cronos kept -4.9% of its revenue as net profit, Niagen Bioscience 13.4%.

Side by side, latest fiscal year

CRONNAGE
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$193.4M$129.4M
Revenue growth+19.5%+29.9%
Net income-$9.4M$17.4M
Net margin-4.9%13.4%
Free cash flow$149Kn/a
Free cash flow margin0.1%n/a
Earnings per share (diluted)-$0.02$0.20
Cash$791.8M$64.8M
Debtn/an/a
Price to earningsn/a15.3
Market value$1.2B$241.3M
Dividend yieldn/an/a
Rank by revenue in sector#254 of 523 · Health care#282 of 523 · Health care

Over the years

Revenue
CRON FY2019: $13.2MCRON FY2019: $25.6MCRON FY2020: $54.4MCRON FY2021: $79.6MCRON FY2022: $109.3MCRON FY2023: $120.3MCRON FY2024: $161.8MCRON FY2025: $193.4MNAGE FY2018: $31.6MNAGE FY2019: $46.3MNAGE FY2020: $59.3MNAGE FY2021: $67.4MNAGE FY2022: $72.1MNAGE FY2023: $83.6MNAGE FY2024: $99.6MNAGE FY2025: $129.4MFY18FY19FY20FY21FY22FY23FY24FY25
CRON $193.4MNAGE $129.4M
Net income
CRON FY2019: -$21.6MCRON FY2019: $1.2BCRON FY2020: -$73.1MCRON FY2021: -$396.1MCRON FY2022: -$168.7MCRON FY2023: -$74MCRON FY2024: $41.1MCRON FY2025: -$9.4MNAGE FY2018: -$33.3MNAGE FY2019: -$32.1MNAGE FY2020: -$19.9MNAGE FY2021: -$27.1MNAGE FY2022: -$16.5MNAGE FY2023: -$4.9MNAGE FY2024: $8.6MNAGE FY2025: $17.4MFY18FY19FY20FY21FY22FY23FY24FY25
CRON -$9.4MNAGE $17.4M
Net margin
CRON FY2019: -163.5%CRON FY2019: 4,549.7%CRON FY2020: -134.6%CRON FY2021: -497.5%CRON FY2022: -154.4%CRON FY2023: -61.5%CRON FY2024: 25.4%CRON FY2025: -4.9%NAGE FY2018: -105.6%NAGE FY2019: -69.4%NAGE FY2020: -33.6%NAGE FY2021: -40.2%NAGE FY2022: -23.0%NAGE FY2023: -5.9%NAGE FY2024: 8.6%NAGE FY2025: 13.4%FY18FY19FY20FY21FY22FY23FY24FY25
CRON -4.9%NAGE 13.4%
Revenue growth
CRON FY2019: +93.7%CRON FY2020: +112.0%CRON FY2021: +46.5%CRON FY2022: +37.3%CRON FY2023: +10.0%CRON FY2024: +34.5%CRON FY2025: +19.5%NAGE FY2019: +46.7%NAGE FY2020: +28.0%NAGE FY2021: +13.8%NAGE FY2022: +6.8%NAGE FY2023: +16.0%NAGE FY2024: +19.2%NAGE FY2025: +29.9%FY19FY20FY21FY22FY23FY24FY25
CRON +19.5%NAGE +29.9%
Free cash flow
CRON FY2019: -$95.8MCRON FY2019: -$169.9MCRON FY2020: -$176.3MCRON FY2021: -$164.8MCRON FY2022: -$92.4MCRON FY2023: -$45.3MCRON FY2024: $6.4MCRON FY2025: $149KNAGE FY2018: -$22.2MNAGE FY2019: -$21.2MFY18FY19FY20FY21FY22FY23FY24FY25
CRON $149KNAGE -$21.2M

Fiscal years as each company reports them; the two may end in different months.

Questions about Cronos and Niagen Bioscience

Which is bigger by revenue, Cronos or Niagen Bioscience?

Cronos is bigger by revenue: $193.4M in fiscal 2025, against $129.4M for Niagen Bioscience in fiscal 2025.

Which keeps more of its revenue as profit, Cronos or Niagen Bioscience?

Cronos had a net margin of -4.9% in fiscal 2025; Niagen Bioscience had 13.4% in fiscal 2025.

Which grew revenue faster, Cronos or Niagen Bioscience?

In their latest fiscal years revenue changed by +19.5% at Cronos and +29.9% at Niagen Bioscience.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies